BioArctic AB has entered into an option, collaboration and license agreement with Novartis Pharma AG for a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed target in neurodegeneration. As part of the initial research collaboration, BioArctic will receive $30 million in upfront payment. Novartis will evaluate the data generated during the initial collaboration and decide whether to exercise their option to license any drug candidate generated. If No...